Equities Analysts Set Expectations for ARTV Q1 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Equities researchers at HC Wainwright boosted their Q1 2025 earnings estimates for Artiva Biotherapeutics in a report released on Wednesday, March 26th. HC Wainwright analyst E. White now expects that the company will earn ($0.68) per share for the quarter, up from their prior forecast of ($0.76). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.89) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($4.10) EPS.

Other equities analysts have also issued reports about the stock. Cantor Fitzgerald decreased their price objective on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday. Wedbush reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Tuesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $20.40.

Artiva Biotherapeutics Stock Down 2.7 %

Shares of ARTV opened at $3.54 on Friday. The stock has a fifty day simple moving average of $4.78 and a two-hundred day simple moving average of $9.29. Artiva Biotherapeutics has a 52-week low of $3.37 and a 52-week high of $17.31.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors have recently modified their holdings of ARTV. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics during the third quarter worth about $42,000. Charles Schwab Investment Management Inc. raised its stake in shares of Artiva Biotherapeutics by 8.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after purchasing an additional 3,233 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after purchasing an additional 3,361 shares during the period. Northern Trust Corp grew its position in Artiva Biotherapeutics by 3.8% in the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after buying an additional 4,335 shares during the last quarter. Finally, Barclays PLC increased its stake in Artiva Biotherapeutics by 23.2% in the 4th quarter. Barclays PLC now owns 24,161 shares of the company’s stock valued at $244,000 after buying an additional 4,545 shares during the period.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.